These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 10699617

  • 1. Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy?
    Sarosdy MF, Schellhammer PF, Johnson R, Carroll K, Kolvenbag GJ.
    Urology; 2000 Mar; 55(3):391-5; discussion 395-6. PubMed ID: 10699617
    [Abstract] [Full Text] [Related]

  • 2. Comparison of goserelin and leuprolide in combined androgen blockade therapy.
    Sarosdy MF, Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Vogelzang NJ, Chodak GW, Klein EA, Schellenger JJ, Kolvenbag GJ.
    Urology; 1998 Jul; 52(1):82-8. PubMed ID: 9671875
    [Abstract] [Full Text] [Related]

  • 3. Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.
    Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G.
    Urology; 1996 Jan; 47(1A Suppl):54-60; discussion 80-4. PubMed ID: 8560679
    [Abstract] [Full Text] [Related]

  • 4. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group.
    Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Sarosdy MF, Vogelzang NJ, Schellenger JJ, Kolvenbag GJ.
    Urology; 1997 Sep; 50(3):330-6. PubMed ID: 9301693
    [Abstract] [Full Text] [Related]

  • 5. A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group.
    Soloway MS, Schellhammer P, Sharifi R, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G.
    Eur Urol; 1996 Sep; 29 Suppl 2():105-9. PubMed ID: 8717471
    [Abstract] [Full Text] [Related]

  • 6. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group.
    Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G.
    Urology; 1995 May; 45(5):745-52. PubMed ID: 7538237
    [Abstract] [Full Text] [Related]

  • 7. Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients.
    Leibowitz RL, Tucker SJ.
    Oncologist; 2001 May; 6(2):177-82. PubMed ID: 11306729
    [Abstract] [Full Text] [Related]

  • 8. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer.
    Crawford ED.
    Urology; 1995 Dec; 46(6):899-901. PubMed ID: 7502440
    [No Abstract] [Full Text] [Related]

  • 9. Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer?
    Labrie F, Candas B, Gomez JL, Cusan L.
    Urology; 2002 Jul; 60(1):115-9. PubMed ID: 12100935
    [Abstract] [Full Text] [Related]

  • 10. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
    Sakai H, Igawa T, Tsurusaki T, Yura M, Kusaba Y, Hayashi M, Iwasaki S, Hakariya H, Hara T, Kanetake H.
    Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of Immediate Switching from Bicalutamide to Flutamide as Second-Line Combined Androgen Blockade.
    Yokomizo Y, Kawahara T, Miyoshi Y, Otani M, Yamanaka S, Teranishi J, Noguchi K, Yao M, Uemura H.
    Biomed Res Int; 2016 Mar; 2016():4083183. PubMed ID: 27493956
    [Abstract] [Full Text] [Related]

  • 12. Clinical efficacy of primary combined androgen blockade for Japanese men with clinically localized prostate cancer unsuitable for local definitive treatment: a single institution experience.
    Kobayashi M, Nukui A, Suzuki K, Kurokawa S, Morita T.
    Int J Clin Oncol; 2011 Dec; 16(6):630-6. PubMed ID: 21512893
    [Abstract] [Full Text] [Related]

  • 13. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival.
    Akaza H, Hinotsu S, Usami M, Arai Y, Kanetake H, Naito S, Hirao Y, Study Group for the Combined Androgen Blockade Therapy of Prostate Cancer.
    Cancer; 2009 Aug 01; 115(15):3437-45. PubMed ID: 19536889
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.